Ilan Gielchinsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ilan Gielchinsky has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Matthijs Jv Scheltema
Garvan Institute of Medical Research and The Kinghorn Cancer Centre Sydney New South Wales Australia
3 shared publications - Ofer Natan Gofrit
Department of Urology, Hadassah Hebrew University Hospital, P.O. Box 12000, Jerusalem 91120, Israel
3 shared publications - Phillip D. Stricker
Garvan Institute of Medical Research 4 , Sydney, Australia
3 shared publications Carlo Yuen
School of Medicine, University of New South Wales, Kensington, NSW, Australia
2 shared publicationsGuy Hidas
Department of Urology, Hadassah Hebrew University Hospital , Jerusalem, Israel
2 shared publicationsMordechai Duvdevani
Department of Urology, Hadassah Hebrew University Hospital , Jerusalem, Israel
2 shared publications
Latest Publications
- Open Access
- 1 January 2023
- Published by Taylor & Francis in Research and Reports in Urology
- Vol. ume 15, 27-35
Focal Irreversible Electroporation for Localized Prostate Cancer – Oncological and Safety Outcomes Using mpMRI and Transperineal Biopsy Follow-Up
Introduction: Irreversible electroporation (IRE) technology for prostate cancer (PC) generates consecutive electrical pulses between pairs of electrodes which move through tumorous cells, irreversibly perforate their membranes and eventually lead to cell death, while avoiding tissue thermal effect. The technique is used for primary focal lesions as well as for focal salvage cases. This series reports short term oncological control, quality of life and safety results. Methods: Retrospective data were collected from 45 consecutive cases of primary (N=38) and salvage (N=7) PC patients treated with IRE. All patients had transperineal MRI/US fusion biopsy and PET-PSMA scan prior to treatment, to verify single lesion. Transperineal Nano-Knife IRE system was used in day-care theatre. Patients had 6 months mpMRI, blood PSA and 1 year confirmatory biopsy following procedure. Quality of life was recorded during the first year. Results: Median primary subgroup analysis (N=38): age 69 years, initial PSA 5.6 ng/dL, lesion size 0.8 mL and ISUP Group 2 (1– 3). Median salvage subgroup analysis (N=7): age 76 years, initial PSA 11.9 ng/dL, lesion size 2.0 mL and ISUP Group 4 (1– 5). Median catheter time 5 (3– 7) days. No Clavien–Dindo> 1 complications were reported nor re-admissions, incontinence, strictures or fistulas. 5% of patients were given PDE-5i drugs. Primary group PSA dropped by 39%, mpMRI clearance in 84%, out-field new lesion in 12%, in-field lesion in 4%. Biopsy at 1 year: 4 patients had out-field clinically significant PC, thus 3 had re-IRE and 1 had radiation therapy. Salvage subgroup MRI clearance was 60%, and 52% remained on active surveillance by 1 year. Conclusion: IRE treatment for focal PC is safe for primary and salvage cases, if done by a meticulously skilled and trained team, and under strict protocols. The short term oncological results are promising especially for primary lesions. Long term oncological results will be published over time.
- 1 January 2023
- Published by Taylor & Francis in Research and Reports in Urology
- Vol. ume 15, 27-35
Open AccessFocal Irreversible Electroporation for Localized Prostate Cancer – Oncological and Safety Outcomes Using mpMRI and Transperineal Biopsy Follow-Up
Introduction: Irreversible electroporation (IRE) technology for prostate cancer (PC) generates consecutive electrical pulses between pairs of electrodes which move through tumorous cells, irreversibly perforate their membranes and eventually lead to cell death, while avoiding tissue thermal effect. The technique is used for primary focal lesions as well as for focal salvage cases. This series reports short term oncological control, quality of life and safety results. Methods: Retrospective data were collected from 45 consecutive cases of primary (N=38) and salvage (N=7) PC patients treated with IRE. All patients had transperineal MRI/US fusion biopsy and PET-PSMA scan prior to treatment, to verify single lesion. Transperineal Nano-Knife IRE system was used in day-care theatre. Patients had 6 months mpMRI, blood PSA and 1 year confirmatory biopsy following procedure. Quality of life was recorded during the first year. Results: Median primary subgroup analysis (N=38): age 69 years, initial PSA 5.6 ng/dL, lesion size 0.8 mL and ISUP Group 2 (1– 3). Median salvage subgroup analysis (N=7): age 76 years, initial PSA 11.9 ng/dL, lesion size 2.0 mL and ISUP Group 4 (1– 5). Median catheter time 5 (3– 7) days. No Clavien–Dindo> 1 complications were reported nor re-admissions, incontinence, strictures or fistulas. 5% of patients were given PDE-5i drugs. Primary group PSA dropped by 39%, mpMRI clearance in 84%, out-field new lesion in 12%, in-field lesion in 4%. Biopsy at 1 year: 4 patients had out-field clinically significant PC, thus 3 had re-IRE and 1 had radiation therapy. Salvage subgroup MRI clearance was 60%, and 52% remained on active surveillance by 1 year. Conclusion: IRE treatment for focal PC is safe for primary and salvage cases, if done by a meticulously skilled and trained team, and under strict protocols. The short term oncological results are promising especially for primary lesions. Long term oncological results will be published over time.
- Open Access
- 9 November 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (11) , 1878
Tubeless Ureterorenoscopy-Our Experience Using a 120 W Laser and Dusting Technique: Postoperative Pain, Complications, and Readmissions
Introduction and Objective: Both double J-stent (DJS) and ureter catheter (UC) drainage represent routine practice following ureterorenoscopy. In select situations, a tubeless approach is possible and safe. In tubeless cases, we use a sheathless dusting technique with the Lumenis® MOSES Pulse™120 H Holmium: YAG laser. We evaluated these three drainage subgroups and compared postoperative pain, complications, and readmissions. Methods: A retrospective database of 269 consecutive patients who underwent primary ureterorenoscopy for the treatment of upper urinary tract stones between October 2018 and August 2019. The cohort was divided according to post-operative drainage as Tubeless, UC, and DJS. The decision on whether to perform post-operative drainage was by surgeon preference. Demographic and clinical parameters such as stone location, number, and burden, hydronephrosis grade, and postoperative complications (fever, acute renal failure, and the obstruction of the upper urinary tract by Stone Street) were assessed. Pain was assessed using a 0–10 Visual Analog Scale score (VAS) and the use of analgesics by dose/case in each group. Results: There were 70 (26%) tubeless, 136 (50%) UC, and 63 (24%) DJS cases. Patients drained with DJSs had a significantly higher stone burden, more severe obstruction, and prolonged operative time. Tubeless and UC-drained patients had the same stone characteristics with maximal diameters of 8.4 (6.1–12) mm and 8 (5.2–11.5) mm in comparison to the stented group, with 12 (8.6–16.6) mm, p < 0.01. The operation time was the longest in the stented group at 49 min (IQR 33–60) in comparison to the UC and tubeless groups at 32 min (23–45) and 28 min (20–40), respectively (p < 0.001). Auxiliary procedures were more prevalent in the stented group, but the overall stone-free rate was not significantly different, p = 0.285. Postoperative ER visits, readmissions, and complications were the highest in the UC-drained group, at 20% in the UC vs. 6% in the tubeless and 10% in the stented groups. Post-operative pain levels and analgesic use were significantly lower in the tubeless group with a significant reduction in opiate usage. Conclusions: A tubeless approach is safe in selected cases with fewer post-operative complications. While DJS should be considered in complex cases, UC may be omitted in straightforward cases since it does not appear to reduce immediate postoperative complications. Those fitted for tubeless procedures had improved postoperative outcomes, facilitating outpatient approach to upper urinary tract stone treatment and patient satisfaction.
- 9 November 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (11) , 1878
Open AccessTubeless Ureterorenoscopy-Our Experience Using a 120 W Laser and Dusting Technique: Postoperative Pain, Complications, and Readmissions
Introduction and Objective: Both double J-stent (DJS) and ureter catheter (UC) drainage represent routine practice following ureterorenoscopy. In select situations, a tubeless approach is possible and safe. In tubeless cases, we use a sheathless dusting technique with the Lumenis® MOSES Pulse™120 H Holmium: YAG laser. We evaluated these three drainage subgroups and compared postoperative pain, complications, and readmissions. Methods: A retrospective database of 269 consecutive patients who underwent primary ureterorenoscopy for the treatment of upper urinary tract stones between October 2018 and August 2019. The cohort was divided according to post-operative drainage as Tubeless, UC, and DJS. The decision on whether to perform post-operative drainage was by surgeon preference. Demographic and clinical parameters such as stone location, number, and burden, hydronephrosis grade, and postoperative complications (fever, acute renal failure, and the obstruction of the upper urinary tract by Stone Street) were assessed. Pain was assessed using a 0–10 Visual Analog Scale score (VAS) and the use of analgesics by dose/case in each group. Results: There were 70 (26%) tubeless, 136 (50%) UC, and 63 (24%) DJS cases. Patients drained with DJSs had a significantly higher stone burden, more severe obstruction, and prolonged operative time. Tubeless and UC-drained patients had the same stone characteristics with maximal diameters of 8.4 (6.1–12) mm and 8 (5.2–11.5) mm in comparison to the stented group, with 12 (8.6–16.6) mm, p < 0.01. The operation time was the longest in the stented group at 49 min (IQR 33–60) in comparison to the UC and tubeless groups at 32 min (23–45) and 28 min (20–40), respectively (p < 0.001). Auxiliary procedures were more prevalent in the stented group, but the overall stone-free rate was not significantly different, p = 0.285. Postoperative ER visits, readmissions, and complications were the highest in the UC-drained group, at 20% in the UC vs. 6% in the tubeless and 10% in the stented groups. Post-operative pain levels and analgesic use were significantly lower in the tubeless group with a significant reduction in opiate usage. Conclusions: A tubeless approach is safe in selected cases with fewer post-operative complications. While DJS should be considered in complex cases, UC may be omitted in straightforward cases since it does not appear to reduce immediate postoperative complications. Those fitted for tubeless procedures had improved postoperative outcomes, facilitating outpatient approach to upper urinary tract stone treatment and patient satisfaction.
- 10 October 2018
- Published by Wiley in BJU International
- Vol. 122 (S5) , 35-41
Prostate cancer in 432 men aged <50 years in the prostate‐specific antigen era: a new outlook
Objective: To evaluate the clinical presentation and treatment outcomes of prostate cancer ( PC a) in 432 consecutive patients aged < 50 years in the prostate‐specific antigen ( PSA ) era. Methods: Retrospective analysis was performed on all patients with PC a (14 570) from the years 1994 to 2017. A total of 432 consecutive patients aged < 50 years were identified. The patients were stratified by D'Amico risk groups, and their clinical presentation and treatment outcomes were analysed. The rates of biochemical recurrence after surgery were compared with the D'Amico prediction model as well as with older propensity‐score‐matched patients. The surgical pathology results in patients undergoing active surveillance (AS) were compared with those of low‐risk patients who underwent immediate surgery. Results: A total of 44%, 42% and 13% of patients harboured low‐risk, intermediate‐risk and high‐risk PC a, respectively. Their median age was 47 years and a positive family history of PC a was reported in 39.1%. Clinical stage was T1 in 65.5% and T2 in 30.0% of patients, and 2.0% of patients had metastatic disease at presentation. Radical prostatectomy ( RP ) was performed in 78.4% of patients ( n = 339) and the biochemical recurrence rates were 7.8% (low‐risk), 15.3% ( intermediate‐risk ) and 23.3% ( high‐risk ) at 5 years post‐surgery. These rates were lower than expected according to the D'Amico prediction model or when compared with older matched patients. A total of 74 patients with low‐risk PC a underwent AS and only 17.6% ( n = 13) required radical treatment after a median follow‐up of 46 months. The surgical pathology results in patients undergoing AS did not differ significantly from patients with low‐risk PCa who underwent immediate surgery (positive surgical margins [ P = 0.145], tumour volume [ P = 0.257] or seminal vesicle involvement [ P = 0.100]). Of the present cohort, only 0.4% died from PC a during a median follow‐up of 65 months. Conclusions: The clinical presentation and prognosis of young patients has changed dramatically during the PSA era. Patients nowadays present with lower‐risk disease that can be treated adequately, with reassuring biochemical recurrence rates at 5 years post‐surgery. AS appears to be safe in patients with low‐risk. PC a.
- 10 October 2018
- Published by Wiley in BJU International
- Vol. 122 (S5) , 35-41
Prostate cancer in 432 men aged <50 years in the prostate‐specific antigen era: a new outlook
Objective: To evaluate the clinical presentation and treatment outcomes of prostate cancer ( PC a) in 432 consecutive patients aged < 50 years in the prostate‐specific antigen ( PSA ) era. Methods: Retrospective analysis was performed on all patients with PC a (14 570) from the years 1994 to 2017. A total of 432 consecutive patients aged < 50 years were identified. The patients were stratified by D'Amico risk groups, and their clinical presentation and treatment outcomes were analysed. The rates of biochemical recurrence after surgery were compared with the D'Amico prediction model as well as with older propensity‐score‐matched patients. The surgical pathology results in patients undergoing active surveillance (AS) were compared with those of low‐risk patients who underwent immediate surgery. Results: A total of 44%, 42% and 13% of patients harboured low‐risk, intermediate‐risk and high‐risk PC a, respectively. Their median age was 47 years and a positive family history of PC a was reported in 39.1%. Clinical stage was T1 in 65.5% and T2 in 30.0% of patients, and 2.0% of patients had metastatic disease at presentation. Radical prostatectomy ( RP ) was performed in 78.4% of patients ( n = 339) and the biochemical recurrence rates were 7.8% (low‐risk), 15.3% ( intermediate‐risk ) and 23.3% ( high‐risk ) at 5 years post‐surgery. These rates were lower than expected according to the D'Amico prediction model or when compared with older matched patients. A total of 74 patients with low‐risk PC a underwent AS and only 17.6% ( n = 13) required radical treatment after a median follow‐up of 46 months. The surgical pathology results in patients undergoing AS did not differ significantly from patients with low‐risk PCa who underwent immediate surgery (positive surgical margins [ P = 0.145], tumour volume [ P = 0.257] or seminal vesicle involvement [ P = 0.100]). Of the present cohort, only 0.4% died from PC a during a median follow‐up of 65 months. Conclusions: The clinical presentation and prognosis of young patients has changed dramatically during the PSA era. Patients nowadays present with lower‐risk disease that can be treated adequately, with reassuring biochemical recurrence rates at 5 years post‐surgery. AS appears to be safe in patients with low‐risk. PC a.
- Open Access
- 1 October 2018
- Published by Taylor & Francis in Research and Reports in Urology
- Vol. ume 10, 145-150
Reduced sensitivity of multiparametric MRI for clinically significant prostate cancer in men under the age of 50
Introduction: Three percent of all new diagnosed prostate cancer (PC) patients are under the age of 50. Multiparametric MRI (mpMRI) is considered as increasingly powerful tool for decision-making in diagnosis of PC and in some active surveillance protocols. Since prostate architecture changes with age, we evaluated the sensitivity of mpMRI to detect clinically significant PC in patients under the age of 50 compared to pair-matched older patients. Methods: Data from a prospective collected and ethics approved database were retrospectively analyzed. We reviewed 1,395 records of PC patients from the years 2012–2017, identifying those under the age of 50 who had radical prostatectomy as primary treatment, a pre-operative mpMRI, a full clinical data set and who had clinically significant cancer (N=51). Tumor size and International Society of Urological Pathology (ISUP) score pair-matching was performed for patients older than 55 years. Clinically significant cancer was defined as ISUP >2 or ISUP 2 with >5% Gleason 4. The sensitivity to detect clinically significant cancer with mpMRI was calculated using pre-operative Prostate Imaging Reporting and Data System (PI-RADS) score and whole-gland final pathology. Results: The median patient age in the young and older groups was 47 and 62, respectively. Both cohorts matched significantly regarding tumor volume (P =0.91) and ISUP score (P =1.0). The median PI-RADS score for the young group was 3, and 4 for the older group. The sensitivity for mpMRI, for PI-RADS 3,4 and 5 was 80.3% (95% CI 66.8%–90.1%) in the young group and 84.3% in the older group (95% CI 71.4%–92.9%), demonstrating no statistically significant difference (P=0.603). Sensitivity of mpMRI for PI-RADS 4,5 was 49.0% (95% CI 34.7%–63.4%) for the young group and 72.5% (95% CI 58.2%–84.1%) for the older group, which differ significantly (P=0.014). Conclusions: mpMRI may have a reduced sensitivity for detecting clinically significant PC in patients under the age of 50 for PI-RADS score 4,5 lesions. Many significant PC lesions were reported as PI-RADS 3 under the age of 50. We recommend that increased significance is placed on PI-RADS 3 lesions found in patients under the age of 50.
- 1 October 2018
- Published by Taylor & Francis in Research and Reports in Urology
- Vol. ume 10, 145-150
Open AccessReduced sensitivity of multiparametric MRI for clinically significant prostate cancer in men under the age of 50
Introduction: Three percent of all new diagnosed prostate cancer (PC) patients are under the age of 50. Multiparametric MRI (mpMRI) is considered as increasingly powerful tool for decision-making in diagnosis of PC and in some active surveillance protocols. Since prostate architecture changes with age, we evaluated the sensitivity of mpMRI to detect clinically significant PC in patients under the age of 50 compared to pair-matched older patients. Methods: Data from a prospective collected and ethics approved database were retrospectively analyzed. We reviewed 1,395 records of PC patients from the years 2012–2017, identifying those under the age of 50 who had radical prostatectomy as primary treatment, a pre-operative mpMRI, a full clinical data set and who had clinically significant cancer (N=51). Tumor size and International Society of Urological Pathology (ISUP) score pair-matching was performed for patients older than 55 years. Clinically significant cancer was defined as ISUP >2 or ISUP 2 with >5% Gleason 4. The sensitivity to detect clinically significant cancer with mpMRI was calculated using pre-operative Prostate Imaging Reporting and Data System (PI-RADS) score and whole-gland final pathology. Results: The median patient age in the young and older groups was 47 and 62, respectively. Both cohorts matched significantly regarding tumor volume (P =0.91) and ISUP score (P =1.0). The median PI-RADS score for the young group was 3, and 4 for the older group. The sensitivity for mpMRI, for PI-RADS 3,4 and 5 was 80.3% (95% CI 66.8%–90.1%) in the young group and 84.3% in the older group (95% CI 71.4%–92.9%), demonstrating no statistically significant difference (P=0.603). Sensitivity of mpMRI for PI-RADS 4,5 was 49.0% (95% CI 34.7%–63.4%) for the young group and 72.5% (95% CI 58.2%–84.1%) for the older group, which differ significantly (P=0.014). Conclusions: mpMRI may have a reduced sensitivity for detecting clinically significant PC in patients under the age of 50 for PI-RADS score 4,5 lesions. Many significant PC lesions were reported as PI-RADS 3 under the age of 50. We recommend that increased significance is placed on PI-RADS 3 lesions found in patients under the age of 50.
- 6 September 2018
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 24 (5) , 268-275
Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments
Diagnostic and Interventional Radiology
- 6 September 2018
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 24 (5) , 268-275
Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments
Diagnostic and Interventional Radiology
- Open Access
- 29 November 2017
- Published by Springer Nature in BMC Research Notes
- Vol. 10 (1) , 641
Urine cell-free microRNA as biomarkers for transitional cell carcinoma
MicroRNA (miRNA) are short nucleotide strands with a regulatory function in the cell. Several miRNAs have been shown to be useful as biomarkers for different neoplasms. The aim of this project was to assess whether levels of miRNA in cell free urine could be used as a biomarker in transitional cell carcinoma (TCC). cDNA libraries were produced based on small RNAs in urine samples of fourteen TCC patients and twenty healthy volunteers. Resulting reads were deep sequenced on Illumina HiSeq sequencer with the intent of characterizing cell free urine miRNA profiles. A statistically significant difference was found for a single miRNA; miR-210 was > sixfold higher in the TCC group compared to the control group. Furthermore, we were able to produce a diagnostic score by summing of standardized levels of overexpressed miRNA. This score was considerably higher in TCC patients with a sensitivity of 0.93, specificity of 0.76 and negative predictive value > 0.97.
- 29 November 2017
- Published by Springer Nature in BMC Research Notes
- Vol. 10 (1) , 641
Open AccessUrine cell-free microRNA as biomarkers for transitional cell carcinoma
MicroRNA (miRNA) are short nucleotide strands with a regulatory function in the cell. Several miRNAs have been shown to be useful as biomarkers for different neoplasms. The aim of this project was to assess whether levels of miRNA in cell free urine could be used as a biomarker in transitional cell carcinoma (TCC). cDNA libraries were produced based on small RNAs in urine samples of fourteen TCC patients and twenty healthy volunteers. Resulting reads were deep sequenced on Illumina HiSeq sequencer with the intent of characterizing cell free urine miRNA profiles. A statistically significant difference was found for a single miRNA; miR-210 was > sixfold higher in the TCC group compared to the control group. Furthermore, we were able to produce a diagnostic score by summing of standardized levels of overexpressed miRNA. This score was considerably higher in TCC patients with a sensitivity of 0.93, specificity of 0.76 and negative predictive value > 0.97.
- 1 July 2017
- Published by SAGE Publications in Journal of Endourology
- Vol. 31 (7) , 701-704
The Transparency of Irrigation Fluids Used in Endoscopic Surgery
Purpose: Transurethral surgery has been traditionally done using the nonelectrolyte, isotonic 1.5% glycine solution as irrigation fluid. The emergence of modern technologies, which can be applied with electrolyte solutions, such as bipolar resection and LASER evaporation, as well as the worry of transurethral resection (TUR) syndrome have driven urologists away from glycine toward the use of physiologic solution. Differences in the transparencies of these fluids have not been studied. Materials and Methods: The ability to resolve two bars at 1 mm apart using a 30° cystoscope lens immersed in different solutions was studied. Physiologic solution, distilled water (DW), and 1.5% glycine solutions containing increasing concentrations of blood, from 0.5% to 2%, were tested. Solutions containing 2% blood were inspected with magnification and microscopy. Results: One-millimeter resolution was reached in as much as 2% blood in 1.5% glycine solution and as much as 1% blood in DW, but in none of the blood–saline solutions. Magnified and microscopic views of 2% blood solutions showed an even distribution of red blood cells (RBCs) in physiologic solution, clumps of RBCs in 1.5% glycine, and an almost complete hemolysis in DW. Conclusions: Glycine solution increases the transparency compared to physiologic solution or DW owing to the clumping of RBCs. When the risk of TUR syndrome is low, as in resection of bladder tumors or small prostates, we propose that 1.5% glycine solution should be preferred over saline, owing to its improved visibility.
- 1 July 2017
- Published by SAGE Publications in Journal of Endourology
- Vol. 31 (7) , 701-704
The Transparency of Irrigation Fluids Used in Endoscopic Surgery
Purpose: Transurethral surgery has been traditionally done using the nonelectrolyte, isotonic 1.5% glycine solution as irrigation fluid. The emergence of modern technologies, which can be applied with electrolyte solutions, such as bipolar resection and LASER evaporation, as well as the worry of transurethral resection (TUR) syndrome have driven urologists away from glycine toward the use of physiologic solution. Differences in the transparencies of these fluids have not been studied. Materials and Methods: The ability to resolve two bars at 1 mm apart using a 30° cystoscope lens immersed in different solutions was studied. Physiologic solution, distilled water (DW), and 1.5% glycine solutions containing increasing concentrations of blood, from 0.5% to 2%, were tested. Solutions containing 2% blood were inspected with magnification and microscopy. Results: One-millimeter resolution was reached in as much as 2% blood in 1.5% glycine solution and as much as 1% blood in DW, but in none of the blood–saline solutions. Magnified and microscopic views of 2% blood solutions showed an even distribution of red blood cells (RBCs) in physiologic solution, clumps of RBCs in 1.5% glycine, and an almost complete hemolysis in DW. Conclusions: Glycine solution increases the transparency compared to physiologic solution or DW owing to the clumping of RBCs. When the risk of TUR syndrome is low, as in resection of bladder tumors or small prostates, we propose that 1.5% glycine solution should be preferred over saline, owing to its improved visibility.
- 1 April 2016
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 195 (4S)
MP91-14 PREGNANCY RATES IN COUPLES WITH A MALE HISTORY OF UNILATERAL TESTICULAR TORSION
- 1 April 2016
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 195 (4S)
MP91-14 PREGNANCY RATES IN COUPLES WITH A MALE HISTORY OF UNILATERAL TESTICULAR TORSION